Mark Rosenblum

Mark Rosenblum

Chief Executive Officer at
Salarius Pharmaceuticals LLC

Net worth: 6 909 $ as of 31/07/2026

72 year
Health Technology
Process Industries
Commercial Services

Profile

Mark J.
Rosenblum
currently serves as Executive VP, Chief Executive & Financial Officer at Salarius Pharmaceuticals LLC starting in 2025.
He is a Member of The American Institute of Certified Public Accountants.
Since 2019, he has been Chief Financial Officer & Executive Vice President at Decoy Therapeutics, Inc. Formerly, he was Chairman & Chief Executive Officer at ActiveCare, Inc. from 2017 to 2019.
From 1985 to 2003, he was Chief Accounting Officer, VP & Controller at Wellman, Inc. He was Chief Financial Officer & Secretary at Hemobiotech, Inc. from 2005 to 2009.
From 2010 to 2014, he held the roles of Chief Financial Officer, Secretary & Senior VP at Advaxis, Inc. He was Chief Financial Officer at Vaneltix Pharma, Inc. from 2014 to 2015.
He was Chief Executive & Financial Officer at Salarius Pharmaceuticals, Inc. in 2025.
He was a Member of the South Carolina Association of Certified Public Accountants.
Education includes undergraduate and graduate degrees from the University of South Carolina.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
0.26%
20/07/2026 1,681 ( 0.26% ) 6 909 $ 31/07/2026

Mark Rosenblum active positions

CompaniesPositionStart
Corporate Officer/Principal -
Chief Executive Officer 17/08/2025

Former positions of Mark Rosenblum

CompaniesPositionEnd
ACTIVECARE INC Chief Executive Officer 01/03/2019
Director of Finance/CFO 01/07/2015
AYALA PHARMACEUTICALS, INC. Director of Finance/CFO 01/04/2014
Director of Finance/CFO 31/12/2009
Comptroller/Controller/Auditor 01/06/2003
See the detail of Mark Rosenblum's experience

Training of Mark Rosenblum

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

49

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Mark Rosenblum